Solid Tumors Clinical Trials in San Francisco, California

7 studies are recruiting for solid tumors in San Francisco, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

   The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-u…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0004), San Francisco, California

   Locations

   782 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT03486873 on ClinicalTrials.gov

2. A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

   This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer agents. The trial w…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Local Institution - 0096, San Francisco, California

   Locations

   58 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07492680 on ClinicalTrials.gov

3. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

   The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Investigative Site US034, San Francisco, California

   Locations

   229 in total

   Run by

   Incyte Corporation

   See if you can join NCT07522073 on ClinicalTrials.gov

4. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

   The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanc…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Locations

   42 in total

   Run by

   ORIC Pharmaceuticals

   See if you can join NCT05315700 on ClinicalTrials.gov

5. A Study of ZL-1310 in Participants With Selected Solid Tumors

   A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco/Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   23 in total

   Run by

   Zai Lab (Shanghai) Co., Ltd.

   See if you can join NCT06885281 on ClinicalTrials.gov

6. Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

   A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Medical Center at Mount Zion, San Francisco, California

   Locations

   16 in total

   Run by

   Tyra Biosciences, Inc

   See if you can join NCT06915753 on ClinicalTrials.gov

7. A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

   The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors, including rare BRAF V600E…

   Stage

   Phase 2

   Ages

   8 and older

   Site

   UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   70 in total

   Run by

   Fore Biotherapeutics

   See if you can join NCT05503797 on ClinicalTrials.gov